Author: Global Cancer Consortium

Neo Matrix is a medical devices company that has developed a novel diagnostic test to determine breast cancer risk. The company’s test uses breast fluid to analyze the presence of normal, pre-malignant and malignant cells. Unlike traditional tests that detect cell tumor lumps in the breast when cancer has advanced into a mature state, this test can detect cancer risk years before tumor build up. The test is a non-invasive, 5 minute procedure that is fully automated and can be used in busy primary care settings, yet still provides doctors with advanced diagnostic results.  Novel diagnostics that can identify the…

Read More

Wednesday, March 23 – Thursday, March 24, 2011 Washington, DC Metro Area The Liaison Capitol Hill 415 New Jersey Avenue, NW Washington, DC 20001 Molecular Diagnostics And the Changing Landscape is an interactive two day seminar hosted by the Medical Technology Learning Institute, the educational arm of AdvaMed,that includes government and industry speakers addressing current regulatory, reimbursement and legislative topics in the evolving field of molecular diagnostics. Attendees will participate in sessions ranging from the latest government policies aimed at molecular diagnostics, healthcare reform and implications for diagnostic; FDA oversight and regulation of molecular diagnostics; key regulatory considerations in developing…

Read More

Women should be aware that they have several options for colon cancer screening, and not only the often-dreaded colonoscopy, according to a new report from the American College of Obstetricians and Gynecologists.

Read More